Elmind Capital LP Buys Shares of 112,000 Amylyx Pharmaceuticals, Inc. $AMLX

Elmind Capital LP purchased a new stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 112,000 shares of the company’s stock, valued at approximately $2,011,520,000. Amylyx Pharmaceuticals accounts for about 0.5% of Elmind Capital LP’s holdings, making the stock its 28th biggest holding. Elmind Capital LP owned 0.10% of Amylyx Pharmaceuticals as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. KBC Group NV purchased a new position in Amylyx Pharmaceuticals in the first quarter worth about $26,000. Meeder Asset Management Inc. purchased a new stake in shares of Amylyx Pharmaceuticals during the 4th quarter valued at about $25,000. State of Wyoming bought a new position in shares of Amylyx Pharmaceuticals in the 2nd quarter worth approximately $40,000. Caitong International Asset Management Co. Ltd lifted its stake in shares of Amylyx Pharmaceuticals by 954.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,859 shares of the company’s stock worth $47,000 after purchasing an additional 3,493 shares during the period. Finally, California State Teachers Retirement System purchased a new position in shares of Amylyx Pharmaceuticals in the second quarter worth approximately $28,000. 95.84% of the stock is currently owned by hedge funds and other institutional investors.

Amylyx Pharmaceuticals Stock Down 1.8%

NASDAQ AMLX opened at $37.46 on Wednesday. The firm has a market cap of $4.17 billion, a price-to-earnings ratio of -26.20 and a beta of -0.21. The business has a 50-day moving average price of $21.28 and a 200-day moving average price of $17.03. Amylyx Pharmaceuticals, Inc. has a twelve month low of $8.48 and a twelve month high of $41.14.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.03). Research analysts expect that Amylyx Pharmaceuticals, Inc. will post -1.48 EPS for the current fiscal year.

Analysts Set New Price Targets

AMLX has been the subject of a number of research reports. Guggenheim upped their target price on shares of Amylyx Pharmaceuticals from $40.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, August 19th. Wall Street Zen cut shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. HC Wainwright boosted their price objective on shares of Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, August 18th. Robert W. Baird upped their price objective on Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 19th. Finally, Mizuho upped their price objective on Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 18th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Amylyx Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $36.25.

Insider Activity at Amylyx Pharmaceuticals

In other news, insider Gina Mazzariello sold 15,000 shares of the firm’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $18.32, for a total transaction of $274,800.00. Following the completion of the transaction, the insider owned 194,090 shares in the company, valued at $3,555,728.80. This trade represents a 7.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 10.90% of the stock is owned by company insiders.

Amylyx Pharmaceuticals Company Profile